Annias Immunotherapeutics, Inc., (spin off from Duke Medical Center) is a biopharmaceutical company focused on the development of novel immunotherapeutic approaches to treat cancer.
Annias has exclusive rights to the Duke University portfolio of Immunotherapy patents, that cover both broadly (immunotherapy of cancer by targeting Cytomegalovirus) and narrowly (composition of PEP-CMV therapeutic).
No review box found! Insert a valid box ID.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
Its proprietary immunotherapeutic platform was discovered by John Sampson and Duane Mitchell at Duke University that targets human Cytomegalovirus (CMV) and in two consecutive clinical trials on patients with GBM, using CMV pp65 loaded dendritic cells (DCs) it remarkably increases progression-free survival.
In 2012, Annias received STTR Phase I grant for the early preclinical level development of CMV therapeutic vaccine for the treatment of Glioblastoma.
Recover your password.
A password will be e-mailed to you.